Thư viện tập trung - Thư viện điện tử

Sách, tuyển tập

Tài liệu điện tử

Can type 2 diabetes and its associated complications be prevented or delayed in people with intermediate hyperglycaemia? / Stinton, Chris;Herath, Deshani;Parr, Janette;Mansbridge, Alice;Williams, Hannah;Rotar, Oxana;Grove, Amy;Al-Khudairy, Lena;Kudrna, Laura;A. Johnson, Samantha;Oyebode, Oyinlola;Taylor-Phillips, Sian

Tác giả : Stinton, Chris;Herath, Deshani;Parr, Janette;Mansbridge, Alice;Williams, Hannah;Rotar, Oxana;Grove, Amy;Al-Khudairy, Lena;Kudrna, Laura;A. Johnson, Samantha;Oyebode, Oyinlola;Taylor-Phillips, Sian

Nhà xuất bản : World Health Organization. Regional Office for Europe

Năm xuất bản : 2024

ISBN : 9789289061230 (PDF); 9789289061247 (print)

Tùng thư : Health Evidence Network synthesis report

Chủ đề : 1. Diabetes Mellitus, Type 2. 2. Population. 3. Public Health Practice. 4. Randomized Controlled Trial. 5. Systematic Review. 6. Publications.

Chia sẻ

Thông tin chi tiết

Tóm tắt :

Diabetes affects one in 11 adults in the WHO European Region. It is a key risk factor for cardiovascular diseases, kidney failure, vision loss and nerve damage. Intermediate hyperglycaemia is a state in which blood glucose levels are above the normal range but below the threshold for diabetes. It is associated with an increased risk for type 2 diabetes, obesity, cardiovascular diseases and mortality. This review assessed the effects of interventions for people with intermediate hyperglycaemia. Results from randomized controlled trials indicate that the risk of developing type 2 diabetes in people with intermediate hyperglycaemia is reduced by lifestyle and (some) pharmacological interventions. Most of the available evidence did not find a difference in mortality or other serious health outcomes for either pharmacological or lifestyle interventions. However, the follow-up periods may have been too short for health outcomes to have emerged. The current evidence suggests that the risk of developing type 2 diabetes is reduced through intervention at the point of intermediate hyperglycaemia, but that the effects of these interventions on long-term health outcomes are unclear. xii, 213 p.

Chia sẻ

Hiển thị MARC

Thông tin dữ liệu nguồn

Thư viện	Ký hiệu xếp giá	Dữ liệu nguồn
Tổ chức y tế thế giới		https://iris.who.int/handle/10665/378139

Ldr		00025nam a2200024 a 4500
001		CLN251847817
020	__	$a9789289061247 (print)
020	__	$a9789289061230 (PDF)
022	__	$a2789-9217
041	__	$aen
100	__	$aStinton, Chris
245	__	$aCan type 2 diabetes and its associated complications be prevented or delayed in people with intermediate hyperglycaemia? /$cStinton, Chris;Herath, Deshani;Parr, Janette;Mansbridge, Alice;Williams, Hannah;Rotar, Oxana;Grove, Amy;Al-Khudairy, Lena;Kudrna, Laura;A. Johnson, Samantha;Oyebode, Oyinlola;Taylor-Phillips, Sian
260	__	$bWorld Health Organization. Regional Office for Europe ,$c2024
490	__	$aHealth Evidence Network synthesis report$v80
520	__	$axii, 213 p.
520	__	$aDiabetes affects one in 11 adults in the WHO European Region. It is a key risk factor for cardiovascular diseases, kidney failure, vision loss and nerve damage. Intermediate hyperglycaemia is a state in which blood glucose levels are above the normal range but below the threshold for diabetes. It is associated with an increased risk for type 2 diabetes, obesity, cardiovascular diseases and mortality. This review assessed the effects of interventions for people with intermediate hyperglycaemia. Results from randomized controlled trials indicate that the risk of developing type 2 diabetes in people with intermediate hyperglycaemia is reduced by lifestyle and (some) pharmacological interventions. Most of the available evidence did not find a difference in mortality or other serious health outcomes for either pharmacological or lifestyle interventions. However, the follow-up periods may have been too short for health outcomes to have emerged. The current evidence suggests that the risk of developing type 2 diabetes is reduced through intervention at the point of intermediate hyperglycaemia, but that the effects of these interventions on long-term health outcomes are unclear.
650	_2	$aSystematic Review
650	_2	$aDiabetes Mellitus, Type 2
650	_2	$aPopulation
650	_2	$aPublic Health Practice
650	_2	$aRandomized Controlled Trial
655	__	$aPublications
700	__	$aHerath, Deshani
700	__	$aParr, Janette
700	__	$aMansbridge, Alice
700	__	$aWilliams, Hannah
700	__	$aRotar, Oxana
700	__	$aGrove, Amy
700	__	$aAl-Khudairy, Lena
700	__	$aKudrna, Laura
700	__	$aA. Johnson, Samantha
700	__	$aOyebode, Oyinlola
700	__	$aTaylor-Phillips, Sian
856	__	$uhttps://iris.who.int/handle/10665/378139
900		1
907		https://iris.who.int/bitstream/handle/10665/378139/9789289061230-eng.pdf.jpg?sequence=4&isAllowed=y
925		G
926		0
927		SH

Thông tin dữ liệu nguồn

Tài liệu cùng tác giả

Lời ngỏ

Mục đích và phương châm hoạt động

Bản quyền